According to a recent study by Renub Research, the Japan Age-Related Macular Degeneration (AMD) Market is forecast to reach US$ 897.79 million by 2033, up from US$ 526.46 million in 2024, growing at a CAGR of 6.11% from 2025 to 2033. This market expansion is being driven by the rising prevalence of AMD among Japan’s aging population, growing demand for early diagnosis, and the advent of cutting-edge therapies including gene therapy.
📊 Rising Incidence of AMD in Japan
Age-related macular degeneration is one of the leading causes of vision loss in older adults, especially those over 50. As Japan continues to have one of the world’s oldest populations, the prevalence of AMD is naturally increasing. The Japanese government’s proactive stance on eye health, along with growing public awareness, is encouraging early diagnosis and intervention.
AMD occurs in two major forms: dry (atrophic) and wet (neovascular). While dry AMD is more common, wet AMD is more severe and responsible for the majority of vision loss. This leads to strong demand for anti-VEGF therapies and newer gene therapy solutions.
💉 Technological Innovations and Gene Therapy Fueling Growth
The development of gene therapy and sustained-release drug delivery systems has significantly boosted the treatment paradigm. These advanced therapies provide longer-lasting effects and improve patients’ quality of life by reducing the frequency of injections.
Japan’s regulatory environment is also facilitating fast-track approvals for innovative treatments. For instance, multiple global pharma companies are launching or trialing biosimilars and new molecular entities for treating wet AMD in the Japanese market.
🏥 Institutional Support and Research Collaboration
Academic institutions and pharmaceutical companies in Japan are collaborating to research novel AMD solutions. Government grants and healthcare initiatives focused on chronic disease management and vision care further support the market’s growth.
Hospitals and specialized ophthalmology clinics are investing in optical coherence tomography (OCT) systems, a crucial diagnostic tool for AMD. Meanwhile, Point-of-Care Testing (POCT) is gaining popularity for quicker screening and diagnosis, particularly in rural and aging communities.
📍 Regional Growth Patterns in Japan
Urban centers like Tokyo, Osaka, and Nagoya dominate the market due to better healthcare access and higher concentration of the elderly population. However, rural regions are also witnessing increased AMD prevalence, leading to greater investment in mobile eye care units and regional outreach programs.
🔬 Market Segmentation Overview
By Type:
- Dry AMD
- Wet AMD
By Drug Class:
- Anti-VEGF Injections (e.g., Ranibizumab, Aflibercept, Brolucizumab)
- Photodynamic Therapy
- Gene Therapy (Emerging)
- Other Adjunctive Therapies
By End User:
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgery Centers (ASCs)
🌐 Key Players in the Japan AMD Market
- Novartis AG
- Bayer AG
- Regeneron Pharmaceuticals
- Roche Holding AG
- Kubota Vision Inc.
- Santen Pharmaceutical Co., Ltd.
These companies are actively involved in developing novel therapies and participating in government partnerships and clinical trials to advance AMD treatment options in Japan.
🔗 Explore Full Report – Japan Age-Related Macular Degeneration Market Size, Share, Forecast 2025-2033
❓ Frequently Asked Questions (FAQs)
1. What is the market size of Japan’s Age-Related Macular Degeneration (AMD) industry?
The market is projected to reach US$ 897.79 million by 2033 from US$ 526.46 million in 2024.
2. What is the CAGR of the Japanese AMD market during the forecast period?
The market is expected to grow at a CAGR of 6.11% from 2025 to 2033.
3. What are the main drivers of this market?
Key drivers include the aging population, advancements in gene therapy, increased government support, and early detection through OCT and POCT devices.
4. Which AMD type is most prevalent in Japan?
Dry AMD is more prevalent, but wet AMD leads in terms of treatment volume due to its severity.
5. What is gene therapy’s role in AMD treatment?
Gene therapy is emerging as a next-generation treatment for wet AMD, offering long-lasting results and potentially reducing the need for frequent injections.
6. Which are the leading drugs in the Japanese AMD market?
Notable drugs include Lucentis (Ranibizumab), Eylea (Aflibercept), and emerging biosimilars and gene therapies.
7. How is the Japanese government supporting AMD treatment?
Through healthcare subsidies, research grants, fast-track drug approvals, and public awareness campaigns for vision care.
8. What end-users dominate this market?
Hospitals and specialized ophthalmic clinics are the primary end users, with growing adoption in ASCs and mobile care centers.
9. Are there region-specific trends in Japan?
Yes. Urban areas have advanced diagnostic and treatment capabilities, while rural areas are seeing expansion via outreach and mobile clinics.
10. Who are the major players in the market?
Companies such as Novartis, Roche, Regeneron, and Santen are leading the market with robust R&D and product pipelines.
🧬 Future Outlook of Japan AMD Market
Japan’s AMD market is at a pivotal juncture, where aging demographics, innovation in therapeutics, and institutional support converge to create a fertile ground for sustainable market growth. By 2033, gene therapy could revolutionize how AMD is treated, reducing patient burden and improving outcomes.
Furthermore, the country’s focus on preventive healthcare, patient education, and early screening technologies positions it as a key player in the global ophthalmology industry.
New Publish Report:
- UAE Non-Invasive Prenatal Testing Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- UAE Quick Service Restaurant (QSR) Market Forecast 2025-2033
- United Arab Emirates (UAE) Organic Dairy Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
🏢 📊 About the Company – Renub Research
📌 Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting.
We provide a wide range of business research solutions that help companies make better business decisions. We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Our wide clientele includes key players in:
✅ Healthcare
✅ Travel & Tourism
✅ Food & Beverages
✅ Power & Energy
✅ Information Technology
✅ Telecom & Internet
✅ Chemicals
✅ Logistics & Automotive
✅ Consumer Goods & Retail
✅ Building & Construction
✅ Agriculture
Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in:
🎓 Finance
🎓 Marketing
🎓 Human Resources
🎓 Bio-Technology
🎓 Medicine
🎓 Information Technology
🎓 Environmental Science
… and more.
📞 Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com